Inhibitory effect of polygonatum polysaccharide on proliferation of bladder cancer cells
WANG Jin-zhu,CAI Ke-ke,YANG Tuo
Department of Urology, Tianjin Integrated Traditional Chinese and Western Medicine Hospital, Nankai University Affiliated Nankai Hospital, Tianjin Key Laboratory of Acute Abdominal Organ Injury and Repair of Traditional Chinese and Western Medicine, Tianjin300110, China
Abstract:
Objective To investigate the inhibitory effects of polygonatum sibiricum polysaccharide (PSP) on the proliferation of bladder cancer (BC) cells and explore the underlying mechanisms. Methods T24 and 5637 bladder cancer cell lines were treated with PSP for 24 hours. Cell viability was assessed by CCK-8 assay, and colony formation assay was used to evaluate cell growth and proliferation. Immunoblotting was employed to analyze apoptosis, and was used to detect the expression of glycolysis-related proteins to explore the inhibitory effect of PSP on glycolysis. Results Compared with the control group, PSP significantly inhibited the proliferation of bladder cancer cells, cell viability decreased to 58% and 52% at 20 μg/mL, and decreased to 32% and 27% at 50 μg/mL (P <0.001), and significantly inhibited colony formation (P <0.001). PSP significantly promoted the apoptosis of bladder cancer cells, and the percentage of apoptosis increased with the increase of PSP concentration, Bax and cleaved caspase-3 were significantly increased, and Bcl-2 was significantly decreased, indicating the promotion of apoptosis (P <0.001). PSP could significantly inhibit the expression of glycolysis and related proteins in bladder cancer cell lines, and the expression levels of HK2 and LDHA were significantly decreased, with gradient effect (P <0.001); PSP treatment significantly inhibited the phosphorylation of STAT3 and decreased the expression of TLR4 (P <0.001), indicating that PSP is a molecular pathway that inhibits the apoptosis and proliferation of bladder cancer by inhibiting TLR4/STAT3 signaling pathway. Conclusion PSP is a potential therapeutic agent for bladder cancer, capable of inhibiting cell proliferation, promoting apoptosis, suppressing glycolysis, and exerting its effects through the TLR4/STAT3 signaling pathway, demonstrating significant potential in the treatment of bladder cancer.
